Suggested Remit: To evaluate the benefits and costs of avalglucosidase alfa within its marketing authorisation for treating Pompe disease for national commissioning by NHS England.
Status In progress
Process STA 2018
ID number 3737

Provisional Schedule

Committee meeting: 1 07 June 2022
Expected publication 17 August 2022

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Key events during the development of the guidance:

Date Update
27 September 2021 Invitation to participate
08 September 2021 In July/August 2020, NICE completed a consultation exercise on the draft scope and routing for this proposed appraisal. Following the consultation, the Topic Selection Oversight Panel (with membership from NICE, Department of Health and Social Care (DHSC) and NHS England and Improvement) met to consider the suitability of this topic. The panel concluded that it will proceed within the NICE work programme as a technology appraisal (TA).
02 September 2021 In progress. -
11 September 2020 (10:00) Scoping workshop
14 July 2020 - 11 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance